Empagliflozin and renal histological changes in an experimental model of heart failure in male rats
Abstract
Renal dysfunction in heart failure (HF) involves congestion-associated injury, tubular damage, and inflammatory remodeling. Although SGLT2 inhibitors improve renal outcomes in HF, associated renal structural changes in nondiabetic HF remain incompletely characterized. Kidney samples from a previously published cohort of nondiabetic male Wistar rats with myocardial infarction-induced HF treated with empagliflozin (10 mg/kg/day) or vehicle for 4 weeks were analyzed histologically and by immunohistochemistry. Congestion-associated histological changes, tubular atrophy, tubular morphometric changes, CD68+ macrophages, CD206+ macrophages, and CD3+ T lymphocytes were evaluated. HF animals exhibited increased congestion-associated histological scores and tubular atrophy compared with sham controls. Empagliflozin was associated with lower congestion-associated scores in HF animals (median 1 [1] vs. 3.5 [3, 4], p = 0.0401) and reduced tubular atrophy (median 1 [0-1] vs. 3 [1-3.75], p = 0.0150). Empagliflozin did not reduce total CD68+ macrophage counts in HF animals, but was associated with increased CD206+ macrophage representation (9.0 ± 1.9 vs. 5.5 ± 1.6 cells/field, p = 0.0058), reduced CD3+ T-cell infiltration (12.0 ± 3.5 vs. 21.0 ± 8.0 cells/field, p = 0.0051), and increased tubular large-lumen profiles. Empagliflozin was associated with attenuation of congestion-associated histological changes, reduced tubular atrophy, tubular morphometric remodeling, and altered renal immune…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.